Cyprotex announce that it has formalised its relationship with DILIsym Services, Inc through an agreement to co-market their joint expertise and capabilities in the area of drug induced liver injury (DILI).
The DILI-sim Initiative is a consortium of pharmaceutical and other life science companies led by DILIsym Services, Inc. The Initiative sponsors the development and application of DILIsym®, a mechanistic model of drug induced liver injury (DILI). Cyprotex, which is a centre of excellence for in vitro toxicology, currently supports the Initiative with mechanistic in vitro data. The data generated feeds directly into the DILIsym® model, which in turn uses Quantitative System Toxicology analysis to evaluate potential in vivo hepatotoxic effects. This combined approach has already been successful in understanding the mechanism of hepatotoxicity of TAK-875, a GPR40 agonist in development for type 2 diabetes, which was withdrawn during Phase 3 trials because of unexplained liver injury.
The co-marketing agreement between Cyprotex and DILIsym Services, Inc will cover:
• Development of joint marketing material
• Demonstration of case studies through joint publications, white papers and webinars
• Joint attendance and sponsoring of conferences and other events
• Promotion of each other’s products and services
Cyprotex and DILIsym Services, Inc recently presented a case study at SOT in Baltimore, which demonstrated the advantages of the combined approach.